Vaxcyte COO Jim Wassil Sells Over $1.15m in Company Stock
Vaxcyte Director Teri Loxam Sells Over $720k in Company Stock
Vaxcyte Insider Sold Shares Worth $1,159,635, According to a Recent SEC Filing
Vaxcyte, Inc. (PCVX): Among Hedge Funds' Top Biotech Stock Picks
Vaxcyte to Present at the 2024 Cantor Global Healthcare Conference
Vaxcyte Is Maintained at Outperform by Mizuho
Vaxcyte Analyst Ratings
Mizuho Securities Maintains Vaxcyte(PCVX.US) With Buy Rating
Mizuho Securities analyst Salim Syed maintains $Vaxcyte(PCVX.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 39.4% and a total average return of -6.2% over the
Vaxcyte's VAX-31 Vaccine: A Strong Buy With Increased Revenue Projections and Substantial Market Potential
Express News | Vaxcyte Inc : Mizuho Raises Target Price to $163 From $113
Vaxcyte's Stock Down 3% After Biotech Unveils Share Sale
TD Cowen Maintains Vaxcyte(PCVX.US) With Buy Rating
TD Cowen analyst Tara Bancroft maintains $Vaxcyte(PCVX.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 55.4% and a total average return of 17.7% over the past
Vaxcyte: BofA Securities, Jefferies Among Managers for Offering >PCVX
Vaxcyte Has Granted Underwriters Option for Additional 1,893,203 Shares >PCVX
Vaxcyte Offering Is Expected to Close on September 6 >PCVX
Vaxcyte Shares Being Sold at $103.00 Each >PCVX
Express News | Vaxcyte Inc - Pre-Funded Warrants Are Being Sold at a Public Offering Price of $102.999 per Pre-Funded Warrant.
Vaxcyte Announces Pricing of $1.3 Billion Public Offering
Press Release: Vaxcyte Announces Pricing of $1.3 Billion Public Offering
Vaxcyte Stock Hits Record High on Pneumococcal Vaccine Study Results